Clinical Trial Search

Primary: Proportion of Patients Who Achieve Composite Clinical and Microbiological Success at TOC (Test of Cure Visit) in the Microbiological Modified Intent-to-Treat (m-MITT)…

Primary: Number of Participants With an Investigator Assessment of Clinical Response at the Post Therapy Evaluation (PTE) Visit (ITT Population) — 68; 15; 15; 16 Participants

Primary: Number of Participants With Clinical and Microbiological Response — 45; 46; 35 Participants

Primary: Percentage of Patients Who Attained Microbiological Eradication (MBE) at the Test of Cure (TOC) Visit in the Microbiological Intent to Treat (MITT) Population — 50…

Primary: Percentage of Subjects With Overall Success at Test-of-Cure — 250; 93; 31; 43 Participants

Primary: Patient-reported Symptomatic Response at Day 5 (mMITT Analysis Set): Non-inferiority Hypothesis Test — 276; 276; 103; 124 Participants

Primary: Patient-reported Symptomatic Response at Day 5 (mMITT Analysis Set): Non-inferiority Hypothesis Test — 276; 276; 103; 124 Participants

Primary: Urinary Tract Infection After Percutaneous Nephrostomy Procedure — 5; 10 Percutaneous nephrostomy procedure — p=0.548

Primary: Percentage of Patients With Composite of Microbiological Eradication and Clinical Cure in the Microbiological Modified ITT (mMITT) Population at Day 5 — 88; 91.4; 10.5…

Primary: The Percentage of Subjects Who Have Both a Per-subject Microbiological Outcome of Eradication and a Clinical Outcome of Cure at the Test of Cure (TOC) Visit in the…

Primary: Percentage of Participants With Microbiological Response of Eradication at Test of Cure (TOC) — 80.7 Percentage of participants

Primary: Overall Response (Combined Clinical Cure and Microbiological Eradication) at Test-of-Cure (TOC) in Micro Intent-to-Treat Population — 264; 258 Participants

Primary: Number of Participants With Overall Response at the Test-of-Cure (TOC) Visit in the Microbiological Intent-to-Treat (Micro-ITT) Population — 261; 291; 171; 179…

Primary: Clinical Cure — 140; 123; 10; 27 participants

Primary: Number of Participants Who Were Cured — 120; 130 Participants — p=<0.001

Primary: Percentage of Microbiologic Modified Intent to Treat Resistant (Micro-MITTR) Participants With Overall Success — 62.6; 36.0 percentage of participants

Primary: Clinical Response at Test of Cure (TOC) in Microbiological Modified Intent-to-treat (mMITT) Analysis Set — 6; 8; 129; 132 Participant

Primary: Number of Participants With Infectious Complications — 6; 7; 6; 8 Participants

Primary: Acute Kidney Injury (AKI) Ordinal Scale — 910; 952; 86; 100 Participants

Primary: The Distribution of Children With Renal Scarring at the Outcome Dimercaptosuccinic Acid (DMSA) Renal Scan — 12; 22; 111; 109 Participants — p=0.16

Primary: Number of Participants That Developed Sepsis After Surgery — 5; 6 Participants

Primary: Proportion Of Participants In The Microbiological Modified Intent-To-Treat (m-MITT) Population Who Achieved Overall Success At The End Of Intravenous Treatment Visit…

Primary: To Evaluate the Effect of Oral Supplementation With Lactobacillus Reuteri on the Frequency of Confirmed UTI in Adult Women With Recurrent UTI. — 1.2; 1.3 Number of…

Primary: Number of Patients With an Overall Success — 119; 97 Participants

Primary: Number of Participants Experiencing Urinary Tract Infection Within 6 Weeks of Surgery — 13; 13 Participants — p=0.97

Primary: Number of Subjects With Combined Clinical and Microbiologic Response — 70 Participants

Primary: Number of Participants With Clinical Cure at Day 7 — 13; 12 participants

Primary: Area Under the Plasma Concentration-time Curve (AUC) From Zero (Pre-dose) Over the Dosing Interval (AUC[0-tau]) of Gepotidacin — 20236.2; 29313.8 Hours* nanogram per…

Primary: Total Daily Area Under the Plasma Concentration-time Profile From Time 0 to 24 Hours at Steady-state (AUC0-24,ss) of Aztreonam (ATM) — 922.9; 733.5 Microgram*hour per…

Primary: Incidence of Infection Post Surgery — 0; 7 participants